ReviewMediterranean journal of hematology and infectious diseases2021
Practical Recommendations for the Management of Patients with ITP During the COVID-19 Pandemic.
Review in Mediterranean journal of hematology and infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Immune thrombocytopenic purpura secondary to COVID-19 vaccination: A systematic review.European journal of haematology · 2023Pooled it
- Persistent Immune Thrombocytopenia as a Post-Acute Sequelae of COVID-19: A Case Report.Public health challenges · 2026Article
- The Differential Diagnosis of Thromobocytopenia.Deutsches Arzteblatt international · 2025Review
- Article
- Challenges in treating primary immune thrombocytopenia patients undergoing COVID-19 vaccination: A retrospective study.Open medicine (Warsaw, Poland) · 2024Article
- Article
- How we treat primary immune thrombocytopenia in adults.Journal of hematology & oncology · 2023Review
- Immune Thrombocytopenia Onset and Relapse During the COVID-19 Pandemic. A Monocenter Study.Mediterranean journal of hematology and infectious diseases · 2023Article
- Use and positioning of fostamatinib in the management of primary chronic immune thrombocytopenia: an Italian expert opinion.Therapeutic advances in hematology · 2023Review
- Nationwide Survey on the Use of Thrombopoietin Receptor Agonists (TPO-RA) for the Management of Immune Thrombocytopenia in Current Clinical Practice in Italy.Mediterranean journal of hematology and infectious diseases · 2023Article
- Diagnosis of immune thrombocytopenia, including secondary forms, and selection of second-line treatment.Haematologica · 2022Article
- Immune thrombocytopenia management during COVID-19 pandemic: An Italian monocentric experience.EJHaem · 2022Article
- Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectives.Annals of hematology · 2022Review
- Severe Immune Thrombocytopenia (ITP) Following SARS-CoV-2 mRNA Vaccine in a Girl on Immunosuppressive Treatment and in Prolonged Stable Phase of ITP.Mediterranean journal of hematology and infectious diseases · 2022Article
- Coronavirus disease 2019 (COVID-19) in a pregnant women with treatment resistance thrombocytopenic purpura with and suspicion to HELLP syndrome: a case report.BMC pregnancy and childbirth · 2021Article
- Immune Thrombocytopenic Purpura Cases Following COVID-19 Vaccination.Mediterranean journal of hematology and infectious diseases · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The current COVID-19 pandemic requires revisiting our current approach to major blood disorders, including ITP (Immune Thrombocytopenia), stirring up the production of several disease-specific practical guidelines. This report describes an updated version of consensus-based practical guidelines on the management of ITP, adapted to the Italian health system and social context. It highlights the role of the hematologist in offering guidance for choosing differentiated approaches in relation to specific circumstances and is intended to provide them with a useful tool for sharing the decision-making process with their patients. Probably, the greatest risk to avoid for a patient with suspected, ongoing or relapsed ITP - that is not severe enough to place him or her at risk for major bleeding - is to be infected in non-hospital and hospital healthcare settings. This risk must be carefully considered when adapting the diagnostic and therapeutic approach. More in detail, the document first addresses the appropriate management for COVID-19 negative patients with newly diagnosed ITP or who experience a relapse of previous ITP, according to first and second lines of treatment and then the management of COVID-19 positive patients according to their severity, from paucisymptomatic to those requiring admission to Intensive Cure Units (ICU). The pros and cons of the different treatments required to correct platelet count are discussed, as are some specific situations, including chronic ITP, splenectomy, thromboembolic complication and anti COVID-19 vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.